Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Chemo ± immunotherapy remains utilized for chronic lymphocytic lymphoma in the real-world practice: Unmet needs, treatment patterns, and age disparities in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

JIJavier Pinilla IbarzSCSwetha ChallagullaQFQianhong Fu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows rising BTKi use in chronic lymphocytic lymphoma patients, suggesting unmet needs in aging treatment.

Key Points

  • BTKi therapy was the most common CLL treatment, accounting for 41.1% usage in first-line therapy across the population.
  • The study evaluated healthcare resource utilization, revealing the lowest burden in BTKi patients compared to other regimens.
  • Retrospective study used real-world data from adults with CLL treated from January 2022 to March 2025.
  • Treatment patterns indicate a shift away from immunotherapy in the elderly, highlighting critical healthcare needs.

Cite This Study

Ibarz et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db84https://doi.org/10.1182/blood-2025-2762
View Full Paper
Ask AI
Bookmark
Share